Literature DB >> 34219432

Erlotinib-induced reactive perforating collagenosis in a case of lung adenocarcinoma.

Xia Jiang1, Ting-Ting Song1, Fei Hao1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34219432     DOI： 10.25259/IJDVL_288_20

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  4 in total

1.  Reactive perforating collagenosis during erlotinib therapy.

Authors:  Yasuhiro Suzuki; Toshiyuki Yamamoto
Journal:  Acta Derm Venereol       Date:  2012-03       Impact factor: 4.437

Review 2.  Acquired reactive perforating collagenosis: current status.

Authors:  Anthony Karpouzis; Alexandra Giatromanolaki; Efthimios Sivridis; Constantin Kouskoukis
Journal:  J Dermatol       Date:  2010-07       Impact factor: 4.005

3.  Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis.

Authors:  J Lübbe; O Sorg; P J Malé; J H Saurat; I Masouyé
Journal:  Dermatology       Date:  2008-01-09       Impact factor: 5.366

4.  Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®)).

Authors:  Agnieszka Owczarczyk-Saczonek; Henryk Witmanowski; Waldemar Placek
Journal:  Postepy Dermatol Alergol       Date:  2013-06-20       Impact factor: 1.837
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.